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Elimination kinetics of captopril in patients with renal failure. Capto-
pril kinetics were determined after a 100-mg oral dose of 4C-captopril
in 21 patients with various degrees of renal impairment. Elimination
kinetics of captopril were evaluated by model-independent methods.
The body clearance (CIB) of captopril decreased steadily with decreas-
ing creatinine clearance (Clr) from 5.2 mI/mm/kg for mild renal failure
patients to 1.6 mI/mm/kg for hemodialysis patients during an interdialyt-
ic period. In patients with mild renal impairment, renal and nonrenal
clearances of captopril averaged 2.2 and 3.0 mI/mm/kg, respectively,
and fell (P < 0.001) to 0.2 and 1.5 mI/mm/kg in patients with severe
renal impairment. There were no significant differences in the extent of
total cumulative excretion (fecal plus urinary) of radioactivity over a 96-
to 120-hr period between the patients with mild, moderate, and severe
renal impairment. The 48-hr renal excretion of captopril averaged 29.
21, and 8% of the dose in the mild, moderate, and severe renally
impaired groups. In five additional hemodialysis patients, the mean
dialyzer clearance of captopril averaged 120 mI/mm. Approximately
35% of the dose was recovered in the 4-hr dialysate. Based on the above
findings, a reduction in the dose of captopril is necessary in patients
with renal failure.
Cinetique d'élimination du captopril chez les malades en insuffisance
rénale. La cinetique du captopril a été déterminée après une dose orale
de 100 mg de '4C-captopril chez 21 malades atteints d'insuffisance
rénale a des degres divers. La cinétique d'élimination du captopril a éte
évaluée par des méthodes indépendants du modéle. La clearance
corporelle (CIB) du captopril diminuait progressivement avec Ia baisse
de Ia clearance de Ia créatinine (Clr) de 5,2 mg/mm/kg chez les malades
en insuffisance rénale modérée a 1,6 mi/mm/kg chez les malades en
hemodialyse lors d'une période interdialytique. Chez les malades en
insuflisance rénale modérée, les clearances rénales et non rénales du
captopril étaient en moyenne de 2,2 et 3,0 mI/mm/kg, respectivement, et
chutaient (P < 0,001) a 0,2 et 1,5 mI/mm/kg chez les malades avec une
alteration rénale sévére. II n'y avait pas de differences significatives
dans l'importance de l'excrétion cumulative totale (fécale et urinaire) de
radloactivité sur une période de 96 a 120 heures entre les malades
atteints d'une alteration rénale modérée, moyenne ou sévère. L'excré-
tion rénale de 48 heures du captopril Ctait en moyenne 29, 21, et 8% de
Ia dose dans les groupes avec des alterations rénales modérCes,
moyennes ou sévéres. Chez cinq malades hémodialysés supplemen-
taires, Ia clearance dialytique moyenne du captopril était de 120 mI/mm.
Environ 35% de Ia dose était retrouvee dans un dialysat de 4 heures.
D'après ces résultats, une diminution de Ia dose de captopril est
nécessaire chez les malades en insuffisance rénale.
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Captopril is an orally active inhibitor of the angiotensin-
converting enzyme [1]. It has been found to be an effective
agent in the treatment of renovascular and essential hyperten-
sion as well as treatment-refractory congestive heart failure [2,
3]. The major route of elimination of captopril is urinary
excretion [4—6], and it would be expected that diminished renal
function, often associated with severe hypertension and con-
gestive heart failure, would prolong captopril elimination. Inhi-
bition of angiotensin-converting enzyme activity with captopril
has been shown to be prolonged in patients with renal dysfunc-
tion compared to normal subjects [7]. Thus, a need to reduce
the dosage of captopril during renal failure would be expected.
The purpose of the present study was to determine the kinetics
of a 100-mg oral dose of 14C-captopril in patients with various
degrees of renal insufficiency. The clearance of captopril during
hemodialysis was also determined.
Methods
Patients. Within 5 days prior to drug administration, 18
patients with chronic renal failure were divided into the follow-
ing three groups on the basis of a measurement of glomerular
filtration rate (GFR) as determined by 24-hr endogenous creati-
nine clearance (Clcr): group 1—mild renal impairment (N = 4),
GFR 73 to 53 mI/mm; group 2—moderate renal impairment (N
6), GFR 41 to 23 mI/mm; group 3—severe renal impairment
(N 8), GFR 14 to 4 mI/mm. Three additional patients, who
were maintained on chronic hemodialysis (GFR <1 mI/mm),
were studied during the interdialytic period (group 4). The
kinetics of captopril during hemodialysis were determined in
five additional patients who were maintained on hemodialysis
(group 5). Informed consent was obtained from all patients
(Mayo Clinic, Human Studies, Protocol 43-79). All studies were
conducted in the Clinical Study Unit, St. Mary's Hospital,
Rochester, Minnesota.
Drug administration. Compressed tablets containing 100 mg
'4C-captopril (which contained 46.9 MCi) were used in this
study. Each patient received one of these tablets with 100 ml of
tap water. All fasted for a least 4 hr before and 2 hr after drug
administration. Additional 50-mi volumes of tap water were
given at hourly intervals up to 4 hr after captopril
administration.
Sample collection. For patients in groups 1 to 4, samples of
venous blood (5 ml) were collected into heparinized Vacu-
tainers® (Becton-Dickinson, Rutherford, New Jersey) just be-
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fore drug administration and at frequent intervals up to 48 hr
thereafter. A 3-mi aliquot of each blood sample collected up to
24 hr was immediately mixed with 25 mg of N-ethylmaleimide
(NEM). NEM was added to prevent oxidation of captopril to its
disulfide dimer and conversion to mixed disulfides with endoge-
nous thiol-containing compounds. Because NEM was used,
direct determination of captopril in plasma was not possible.
For hemodialysis clearance studies (group 5), the same dose of
4C-captopril was administered 1 hr prior to hemodialysis.
Blood samples were obtained from the arterial (incoming) and
venous (outgoing) lines of the hemodialyzer at 2, 3, 4, and 5 hr
after drug administration.
Urine samples were collected just prior to captopril adminis-
tration, at four time intervals during the first 24 hr, and then
every 24 hr up to 96 (group 1) or 120 hr (groups 2 to 4) after
captopril administration. For urine collection during the first 48
hr after dosing, sufficient NEM was added to each container
before collection to ensure a final concentration of NEM of at
least I mg/mi. For the urine samples obtained from 48 to 120 hr,
no NEM was added and thus only total radioactivity was
determined.
Total feces were collected for 24 hr before drug and every 24
hr up to 96 (group 1) or 120 hr (groups 2 to 4) thereafter. Feces
were assayed only for total radioactivity.
In group 5, a 30-mi sample of dialysate was collected just
prior to initiation of dialysis, and at 1, 2, 3, and 4 hr during the
hemodialysis procedure. Only total radioactivity was deter-
mined in these samples.
Hemodialysis methods. Hollow fiber dialyzers (Cordis Dow
No. 5, Cordis Dow Corp., Miami, Florida and Travenol CF
1500, Travenol Laboratories, Inc., Morton Grove, Illinois)
were utilized in this study. Dialysate and blood flow rates
averaged 545 5 and 181 6 mI/mm, respectively, during the
4-hr hemodialysis session.
Analysis of samples. Blood, urine, and feces were analyzed
by methods described previously [5, 81. For determination of
captopril, blood was extracted with methanol and the extract
was concentrated and then chromatographed on silica gel
plates. Urine collected for the first 48 hr was chromatographed
directly. The scintillation cocktail of Anderson and McClure [9]
was used and all samples were counted in either of two kinds of
liquid scintillation spectrometers (Packard Tri-Carb, Packard
Instruments, United Technology, Downers Grove, Illinois, or
Intertechnique Model SL-4200, IN/US Service Corp., Fairfield,
New Jersey). Counting efficiencies were determined with auto-
matic external standardization.
Kinetic evaluations. Kinetic evaluations were based on data
obtained from captopril in blood and urine using model-inde-
pendent methods [10]. These methods do not require the
assumption of a specific compartmental model for either drug or
metabolite. Most of the pharmacokinetic parameters are based
on the area under the curve of drug concentration plotted
versus time. The fraction of the dose absorbed (F) was assumed
to be equal to the measured excretion of total radioactivity in
urine over a 96- to 120-hr period. This is justified by a previous
study in healthy subjects in which less than 1% of an intrave-
nous dose of captopril was excreted in the feces [4]. For the
hemodialysis patients, F was assumed to be equal to the mean
value in patients with severe renal failure.
For each patient in groups I to 4, the logarithms of the
concentration of captopril in blood were plotted against time,
and the slope (/3) of the terminal portion of the curve was
obtained by linear regression. Elimination half-life (t/2) of
captopril from blood was determined by In 2/f3. The area under
the curve from time zero to infinity (AUC.,) was determined
as:
AUC. = AUC. + C/f3 (1)
The AUC from time zero to the time of the last blood sample
obtained (t) is and was determined using the trapezoi-
dal rule where C equals concentration of drug in blood at the
time the last sample was obtained.
Renal clearance (CIR) of captopril from blood was determined
as:
- UcPVCIR — (2)
%ULO..,24 hr
where UcpV equals cumulative excretion of captopril in 24 hr.
Body clearance (CIB) of captopril from the blood is the sum of
CIR plus CINR (nonrenal clearance) and was determined as:
—
F x dose of captopril (3)CIB — AUC
In a previous study [5], following the administration of radiola-
beled captopril to normal subjects, only 6 to 14% of the
radioactivity was associated with the cellular elements. There-
fore, CIR and CIB from the plasma were calculated by multiply-
ing the values obtained from blood times 1-hematocrit.
Blood clearance of captopril (Cl) by hemodialysis was deter-
mined as:
Cl = QB — V) 4
where A and V are the arterial and venous blood captopril
concentrations, respectively, and QB is the blood flow rate
through the dialyzer. The amount of total radioactivity (A)
extracted by dialysis was calculated by:
A = DTR (QD) (5)
where DTR equals concentration of total radioactivity in the
dialysate and QD is the dialysate flow rate.
Pharmacokinetic data were analyzed using the one-way anal-
ysis of variance and Duncan's multiple range test for compari-
son between groups. Correlation coefficients were determined
using linear regression analysis. A P value less than or equal to
0.05 was considered statistically significant.
Results
Demographic data and GFRs for all the patients are presented
in Table!.
The cumulative excretion of total radioactivity in the urine
and feces for 96 to 120 hr after drug administration is shown in
Table 2. There were no significant differences in the extent of
cumulative urinary or fecal excretion of radioactivity between
the patients with mild, moderate, or severe renal impairment.
As expected, urinary excretion was significantly reduced in the
hemodialysis group, and fecal elimination of radioactivity was
increased compared to patients with functioning kidneys.
Figure 1 displays blood concentration-time curves for capto-
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4 Hemodialysis 18
19
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X SEM
M
M
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Table 1. Patient data
69
22
52
47.7 13.7
70.6
73.0
58.2
67.3 4.6
0.0
0.0
0.0
0.0
Degree of renal
impairment Urine Feces
pril for all four renally impaired groups. Kinetic data for
captopril is presented in Table 3, In the patients with severe
renal impairment, Cm, was significantly greater (1.1 vs. 0.5
g/ml, P <0.05) than in those maintained on hemodialysis. The
average AUC. for captopril was fourfold higher (8.2 vs. 1.9
x hr/mi, P < 0.001) in patients maintained on hemodialysis
than those with mild renal impairment. CIB fell from 5.2
mI/mm/kg in patients with mild renal impairment to 1.6
mI/mm/kg (P < 0.001) in hemodialysis patients. As shown in
Figure 2, there was a linear correlation between CIB of captopril
and Cl. (P < 0.01). Elimination t of captopril rose from 3.5hr
in patients with mild renal dysfunction to 32 hr in hemodialysis
______
patients.
The 48-hr renal excretion of unchanged drug accounted for
29, 21, and 8% of the dose, in the mild, moderate, and severe
renal failure groups, respectively. CIR fell (P < 0.01) from 2.2
mi/mm/kg in the mild group to 1.2 and 0.2 mI/mm/kg in the
moderate and severe groups, respectively, and was zero in the
hemodialysis patients. In the mild renal failure patients, C1NR
averaged 3.0 mI/mm/kg and declined significantly (P < 0.001) to
1.5 and 1.6 mI/mm/kg in the severe and hemodialysis groups,
respectively.
Arterial blood concentrations of total radioactivity and capto-
pril obtained just before and during the 4-hr hemodialysis
session are shown in Figure 3. Levels of total radioactivity
declined slowly, whereas captopril decreased rapidly. The
mean dialysate clearance for captopril was 120.2 7.1 mI/mm
(Table 4). The amount of total radioactivity extracted by the
dialyzer averaged 34.9 3.1 mg.
Discussion
Because previous studies have shown that about 70% of an
orally administered dose of captopril was excreted in the urine
in healthy subjects [4, 5], it was not unexpected that progressive
decrements in GFR would decrease both renal and total body
elimination and prolong elimination half-life of captopril.
2
Patient no. and Creatinine
degree of renal Age Weight clearance
Group impairment Sex years kg mi/mm
Mild 16
22
26
27
5EM
M
F
F
F
60
54
19
39
43.0 9.0
66.4
57.0
109.5
78.5
77.9 11.4 61
56
53
73
61
4
Moderate
5t
12
17
20
23
24
25
SEM
M
M
F
F
M
M
48
55
42
21
55
51
45.3 5.3 76.2
85.0
91.2
54.3
54.8
76.4
95.6
7.3 32
23
41
29
34
27
38
3
Severe
5
7
8
9
10
11
13
14
15
SEM
F
F
M
F
M
M
F
F
20
59
46
53
62
28
57
19
43.0 6.3 70.2
47.4
87.4
80.4
66.0
90.0
64.0
73.0
53.0
5.5 10
9.7
9.9
II
8
4
12
14
12
I
5 Hemodialysis I F 38 50.6 0.0
2 M 69 73.9 0.0
3 M 22 77.8 0.0
4 M 20 59.4 0.02
5 M 59 88.4 0.03
X SEM 41.6 9.8 70.0 6.7 0.01 0.01
Table 2. Cumulative excretion of total radioactivitya (% of dose) over
96 to 120 hr after drug administration
Mild
Moderate
Severe
Hemodialysis
71.2 4.9
69.0 3.9
59.3 6.43.9 2.0b
17.3 6.0
16.7 4.4
14.1 3.4
36.7 11.2
Total
88.4 1.9
86.3 3.3
73.5 8.2
39.3 9•5h..d
a All values are mean SEM.
b P < 0.05 compared to mild renal impairment.
P < 0.05 compared to moderate renal impairment.
P < 0.05 compared to severe renal impairment.
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Table 3. Pharmacokinetic parametersa of captopril in patients with renal impairment
Abbreviations: C,,ax, maximum concentration in blood; Tmax, time to reach the maximum concentration in blood; AUC,
concentration-time curve; CIR, body clearance; CIR, renal clearance; CINR, nonrenal clearance; t½, elimination half-life.
All values are mean SEM.
P < 0.05 compared to moderate renal impairment.
P < 0.05 compared to severe renal impairment.
P < 0.05 compared to hemodialysis patients.
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1.0
0.8
0.6
0.4
0.2
0.01
0.008
0.006
0.004
0.002
0.001
In a previous study in subjects with normal renal function,
the absolute absorption of '4C-labeled drug was the same
whether determined as the ratios of the blood level AUC..,, or
as ratios of urinary excretion values following oral and intrave-
nous administration [4]. Therefore, the absorption of captopril
was assumed to be equal to the urinary excretion of total
radioactivity in these patients with impaired renal function.
Excluding the hemodialysis patients, there were no significant
differences in the urinary excretion (59 to 71%) of total radioac-
tivity in patients with mild, moderate, and severe renal failure.
These data suggest that captopril absorption is not significantly
altered in uremia. This supposition could be confirmed by
comparing AUCs after oral and intravenous administration in
hemodialysis patients. In hemodialysis patients (Table 2), fecal
excretion of total radioactivity was greater during the interdia-
lytic period than in patients with functioning kidneys. This does
not represent malabsorption of the drug, but rather greater
biliary excretion, since maximum concentration in blood (Cmax)
for captopril in these patients was not significantly different
than in patients with mild renal dysfunction.
CIR of captopril accounted for 50% of its body clearance in
subjects with normal renal function [11]. In the present study,
as renal failure progressed, CIR of captopril fell as expected.
CINR of captopril was also lower in hemodialysis patients (1.6
mllmin/kg) compared to patients with mild renal failure (3.0
mI/mm/kg). A similar decline in the nonrenal elimination of
unchanged drug, in the presence of renal failure, has also been
reported for procainamide [12]. However, the ratio of CINR to
CIR increased from 1.4 for patients with mild renal failure to 7.7
for patients with severe renal failure.
Captopril, which has a molecular weight of 217, was effec-
% of Dose
Degree of
renal
impairment
Cma
gIm1
Tmax
hr
AUC0_.,
x hr/rn!
CIB CIR CINR
tV2
hr
excreted as
captopril
0 to 48 hrmI/mm/kg
Mild 0.8 0.2 1.3 0.3 1.9 0.3.d 5.2 0.3,d 2.2 0.lc.d 3.0 0.4.d 3.5 29.3 3.6h..d
Moderate 0.8 0.1 1.3 0.2 2.6 0.3' 4.0 0.5c,1 1.2 0.3' 2.8 0.4'' 7.7 1.1'' 20.6 2.2c
Severe 1.1 0.2d 0.8 0.1 7.1 1.0 1.8 0.2 0.2 0.1 1.5 0.2 21.1 3.8 7.8 2.ld
Hemodialysis 0.5 0.1 0.7 0.2 8.2 0.7 1.6 0.1 0.0 1.6 0.1 32.0 0.5 0.1 0.1
area under blood
0.1
0.08
0.06
0.04
0.02
0
700
. 600
E
500
a0
a
400
0
5)
C
300
5)5)
C.,
>.
0
.0
5)
0
y = 5.71 CI,, + 84.54
0
00
200
0 0
0)
a.
a0
a
5)U
Time, hours
Fig. 1. Mean SEM concentrations of captopril in blood in all four
renallv impaired groups after a /00 mg oral dose of '4C-captopril.
Symbols are: •, mild renal impairment (N = 4); 0, moderate renal
impairment (N = 6);, severe renal impairment (N = 8): A, hemodialy-
sis (N = 3).
0
0
5
10 20 30 40 50 60 70 80
10 15 20 25
Creatinine clearance, mi/mm
Fig. 2. Linear regression of CIB of captopril and creatinine clearance
for 21 patients.
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Time after drug administration, hours
Fig. 3. Mean SEM concentrations of total radioactivity and cap!opril
in arterial blood during hemodialysis in five patients.
tively removed by hemodialysis, whereas total radioactivity,
which includes higher molecular weight compounds, was not
removed as efficiently. In a previously published study [13], the
clearance of captopril averaged 80 mI/mm for kidney filters with
a surface area of 1.25 m2. This is consistent with our data of a
mean clearance of 120 mI/mm for captopril using larger filters
(such as the Cordis Dow 5, surface area 2.5 m2, and Travenol
CF 1511, surface area 1.5 m2).
As shown in Figure 2, it is apparent that body clearance of
captopril is reduced as renal failure worsens. To avoid unneces-
sary accumulation of captopril, it is suggested that the total
daily dose of this agent be reduced in patients with renal
dysfunction relative to the magnitude of the decrease in renal
function. For instance, in patients with moderate to severe
renal failure, it is prudent to begin dose titration with a 6.25 or
12.5 mg dose, rather than the initial 25 mg dose, as recommend-
ed by the manufacturer, for patients with normal renal function.
If the clinical state of the patient allows, dosage should be
increased slowly in renal dysfunction, and after the desired
therapeutic effect has been achieved, the dose should be back-
titrated slowly to determine the minimal effective dose.
Conversely, instead of reducing the daily dose, the dosage
interval may be progressively prolonged in proportion to the
decrease in renal function. Because the efficacy of a given dose
of captopril is related to the state of sodium balance and activity
Dialysate Total
captopril radioactivity
QB clearance extracted (mg)
Dialyzer ,nllmin mlI,nin in 4-hr dialysis
I Dow5 167 104.6 38.7
2 CFI500 167 115.5 28.7
3 DowS 185 110.0 45.6
4 Dow 5 185 126.3 32.2
5 Dow 5 200 144.8 29.6
Mean — 180.8 120.2 34.9
SEM — 6.2 7.1 3.1
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